Drug Profile
Research programme: fullerine analogues - Tego BioSciences
Alternative Names: DF-1Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Tego BioSciences
- Developer National Cancer Institute (USA); Tego BioSciences
- Class Imaging agents
- Mechanism of Action Antioxidants; Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chemotherapy-induced damage; Neurodegenerative disorders; Radiation injuries
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chemotherapy induced damage (Prevention) in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Radiation injuries (Prevention) in USA
- 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative-disorders in USA